Table 4.
Child-Pugh score at the time of discontinuation due to tumor progression or at the time of discontinuation due to adverse events (a) and secondary treatments (b)
| a | C-P A | C-P 7 | C-P 8 |
| Sorafenib (n = 14) | 2 | 7 | 5 |
| LFP (n = 27) | 19 | 5 | 3 |
| b | Sorafenib (n = 14) | LFP (n = 27) | |
| Best supportive care | 11 | 16 | |
| Sorafenib (continued) | (2) | 6 | |
| HAIC | 1 | 2 | |
| Cisplatin 5-FU continuous1 | 1 | 1 | |
| Interferon + 5-FU | 1 | ||
| TACE | 2 | ||
| Resection of LN metastasis | 1 | ||
The numerical data represent the number of cases. Figures in parentheses represent the total number of cases of discontinuation due to adverse events and tumor progression. 5-FU, 5-fluorouracil; C-P, Child-Pugh; HAIC, hepatic arterial infusion chemotherapy; LFP, low-dose 5-fluorouracil and cisplatin; LN, lymph node; TACE, transarterial chemoembolization.
1
Continuous hepatic arterial infusion of 5-fluorouracil using a reservoir catheter system.